Evidence Comparison
Compare CagriSema, Semaglutide, Tirzepatide side by side using the same BACToBasics evidence dataset that powers the interactive comparison tool. The table below focuses on mechanism, regulatory status, human evidence, safety context, anti-doping context, and primary sources.
Metabolic Combination
Investigational
Phase 3 investigational
Fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist.
CagriSema has regulatory-grade-scale Phase 3 evidence, but it remains an investigational fixed-dose combination and should not be treated as a generic DIY cagrilintide-plus-semaglutide blend.
Open CagriSema evidence guide →Metabolic & Weight Loss
FDA-approved
Regulatory-grade / large Phase 3
Long-acting GLP-1 receptor agonist.
One of the strongest evidence bases on BACToBasics and an important reference point for comparing newer incretin therapies.
Open Semaglutide guide →Metabolic & Weight Loss
FDA-approved
Regulatory-grade / large Phase 3
Dual GIP and GLP-1 receptor agonist.
A dual-incretin therapy with regulatory-grade evidence and a useful comparator for both semaglutide and investigational retatrutide.
Open Tirzepatide guide →Save this comparison
Keep the current two- or three-compound comparison for quick access in My Tools.
Loading comparison tool...
Regulatory status and evidence level are separate ideas. A compound can have meaningful human research and still remain investigational, while an FDA-approved product can have approval only for specific indications and formulations.
BACToBasics also separates direct human intervention evidence from animal, cell, endogenous-biology, or related-molecule evidence so weaker evidence does not inherit the certainty of stronger research.
This page is generated from the same structured evidence records as the main interactive compare tool. Updating a compound's regulatory status, evidence summary, safety context, or source list updates both experiences rather than maintaining separate copies.
Read the Research & Editorial Policy →Evidence behind the comparison
These deep links are generated from the compounds in this comparison, so research and development pages stay connected as the underlying datasets grow.
Open the sourced public research and clinical-development timeline.
Open →
Research2 curated sources in the BACToBasics Research Library.
Open →
DevelopmentApproved · Approved.
Open →
UpdatesOpen the sourced public research and clinical-development timeline.
Open →
Research2 curated sources in the BACToBasics Research Library.
Open →
DevelopmentApproved · Approved.
Open →
Keep comparing
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
BACToBasics provides educational information only. Comparison pages are not medical advice, dosing advice, treatment guidance, anti-doping advice, or recommendations to use any compound.